MINT MINT, Dpt of Biology, University of Rome Tor Vergata MINT http://mint.bio.uniroma2.it/mint url>http://mint.bio.uniroma2.it/mint/ https://mint.bio.uniroma2.it MINT-[0-9]+ https://mint.bio.uniroma2.it/index.php/results-interactions/?id=${ac} The Molecular INTeraction database (MINT) is a relational database designed to store interactions between biological molecules. http://mint.bio.uniroma2.it Multimeric and differential binding of CIN85/CD2AP with two atypical proline-rich sequences from CD2 and Cbl-b*. Multimeric and differential binding of CIN85/CD2AP with two atypical proline-rich sequences from CD2 and Cbl-b*. FEBS J. (1742-464X) 2013 Ceregido MA., Garcia-Pino A., Ortega-Roldan JL., Casares S., López Mayorga O., Bravo J., van Nuland NA., Azuaga AI. suggested by lperfetto in vitro In vitro itc isothermal titration calorimetry ITC ITC itc experimental particp experimental participant identification experimental particp Ceregido MA., Garcia-Pino A., Ortega-Roldan JL., Casares S., López Mayorga O., Bravo J., van Nuland NA., Azuaga AI. suggested by lperfetto FEBS J. (1742-464X) 2013 Multimeric and differential binding of CIN85/CD2AP with two atypical proline-rich sequences from CD2 and Cbl-b*. Multimeric and differential binding of CIN85/CD2AP with two atypical proline-rich sequences from CD2 and Cbl-b*. FEBS J. (1742-464X) 2013 Ceregido MA., Garcia-Pino A., Ortega-Roldan JL., Casares S., López Mayorga O., Bravo J., van Nuland NA., Azuaga AI. suggested by lperfetto in vitro In vitro saxs x ray scattering saxs experimental particp experimental participant identification experimental particp Ceregido MA., Garcia-Pino A., Ortega-Roldan JL., Casares S., López Mayorga O., Bravo J., van Nuland NA., Azuaga AI. suggested by lperfetto FEBS J. (1742-464X) 2013 Multimeric and differential binding of CIN85/CD2AP with two atypical proline-rich sequences from CD2 and Cbl-b*. Multimeric and differential binding of CIN85/CD2AP with two atypical proline-rich sequences from CD2 and Cbl-b*. FEBS J. (1742-464X) 2013 Ceregido MA., Garcia-Pino A., Ortega-Roldan JL., Casares S., López Mayorga O., Bravo J., van Nuland NA., Azuaga AI. suggested by lperfetto in vitro In vitro nmr nuclear magnetic resonance NMR NMR nmr experimental particp experimental participant identification experimental particp Ceregido MA., Garcia-Pino A., Ortega-Roldan JL., Casares S., López Mayorga O., Bravo J., van Nuland NA., Azuaga AI. suggested by lperfetto FEBS J. (1742-464X) 2013 cblb_human E3 ubiquitin-protein ligase CBL-B Signal transduction protein CBL-B SH3-binding protein CBL-B Casitas B-lineage lymphoma proto-oncogene b RING finger protein 56 CBLB RNF56 Nbla00127 RING-type E3 ubiquitin transferase CBL-B protein protein human Homo sapiens Human MANSMNGRNPGGRGGNPRKGRILGIIDAIQDAVGPPKQAAADRRTVEKTWKLMDKVVRLCQNPKLQLKNSPPYILDILPDTYQHLRLILSKYDDNQKLAQLSENEYFKIYIDSLMKKSKRAIRLFKEGKERMYEEQSQDRRNLTKLSLIFSHMLAEIKAIFPNGQFQGDNFRITKADAAEFWRKFFGDKTIVPWKVFRQCLHEVHQISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWGSILRNWNFLAVTHPGYMAFLTYDEVKARLQKYSTKPGSYIFRLSCTRLGQWAIGYVTGDGNILQTIPHNKPLFQALIDGSREGFYLYPDGRSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQESDGQGCPFCRCEIKGTEPIIVDPFDPRDEGSRCCSIIDPFGMPMLDLDDDDDREESLMMNRLANVRKCTDRQNSPVTSPGSSPLAQRRKPQPDPLQIPHLSLPPVPPRLDLIQKGIVRSPCGSPTGSPKSSPCMVRKQDKPLPAPPPPLRDPPPPPPERPPPIPPDNRLSRHIHHVESVPSRDPPMPLEAWCPRDVFGTNQLVGCRLLGEGSPKPGITASSNVNGRHSRVGSDPVLMRKHRRHDLPLEGAKVFSNGHLGSEEYDVPPRLSPPPPVTTLLPSIKCTGPLANSLSEKTRDPVEEDDDEYKIPSSHPVSLNSQPSHCHNVKPPVRSCDNGHCMLNGTHGPSSEKKSNIPDLSIYLKGDVFDSASDPVPLPPARPPTRDNPKHGSSLNRTPSDYDLLIPPLGEDAFDALPPSLPPPPPPARHSLIEHSKPPGSSSRPSSGQDLFLLPSDPFVDLASGQVPLPPARRLPGENVKTNRTSQDYDQLPSCSDGSQAPARPPKPRPRRTAPEIHHRKPHGPEAALENVDAKIAKLMGEGYAFEEVKRALEIAQNNVEVARSILREFAFPPPVSPRLNL B4E307D31B9F0779 sh3k1_human SH3 domain-containing kinase-binding protein 1 SH3KBP1 CIN85 Cbl-interacting protein of 85 kDa Human Src family kinase-binding protein 1 CD2-binding protein 3 protein protein human Homo sapiens Human MVEAIVEFDYQAQHDDELTISVGEIITNIRKEDGGWWEGQINGRRGLFPDNFVREIKKEMKKDPLTNKAPEKPLHEVPSGNSLLSSETILRTNKRGERRRRRCQVAFSYLPQNDDELELKVGDIIEVVGEVEEGWWEGVLNGKTGMFPSNFIKELSGESDELGISQDEQLSKSSLRETTGSESDGGDSSSTKSEGANGTVATAAIQPKKVKGVGFGDIFKDKPIKLRPRSIEVENDFLPVEKTIGKKLPATTATPDSSKTEMDSRTKSKDYCKVIFPYEAQNDDELTIKEGDIVTLINKDCIDVGWWEGELNGRRGVFPDNFVKLLPPDFEKEGNRPKKPPPPSAPVIKQGAGTTERKHEIKKIPPERPEMLPNRTEEKERPEREPKLDLQKPSVPAIPPKKPRPPKTNSLSRPGALPPRRPERPVGPLTHTRGDSPKIDLAGSSLSGILDKDLSDRSNDIDLEGFDSVVSSTEKLSHPTTSRPKATGRRPPSQSLTSSSLSSPDIFDSPSPEEDKEEHISLAHRGVDASKKTSKTVTISQVSDNKASLPPKPGTMAAGGGGPAPLSSAAPSPLSSSLGTAGHRANSPSLFGTEGKPKMEPAASSQAAVEELRTQVRELRSIIETMKDQQKREIKQLLSELDEEKKIRLRLQMEVNDIKKALQSK 3BD350FCDB14BD4C cd2_human T-cell surface antigen CD2 CD2 SRBC Erythrocyte receptor LFA-2 LFA-3 receptor Rosette receptor T-cell surface antigen T11/Leu-5 protein protein human Homo sapiens Human MSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWEKTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEKIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSLSAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN A03D853C3B618917 cd2ap_human CD2-associated protein CD2AP Cas ligand with multiple SH3 domains Adapter protein CMS protein protein human Homo sapiens Human MVDYIVEYDYDAVHDDELTIRVGEIIRNVKKLQEEGWLEGELNGRRGMFPDNFVKEIKRETEFKDDSLPIKRERHGNVASLVQRISTYGLPAGGIQPHPQTKNIKKKTKKRQCKVLFEYIPQNEDELELKVGDIIDINEEVEEGWWSGTLNNKLGLFPSNFVKELEVTDDGETHEAQDDSETVLAGPTSPIPSLGNVSETASGSVTQPKKIRGIGFGDIFKEGSVKLRTRTSSSETEEKKPEKPLILQSLGPKTQSVEITKTDTEGKIKAKEYCRTLFAYEGTNEDELTFKEGEIIHLISKETGEAGWWRGELNGKEGVFPDNFAVQINELDKDFPKPKKPPPPAKAPAPKPELIAAEKKYFSLKPEEKDEKSTLEQKPSKPAAPQVPPKKPTPPTKASNLLRSSGTVYPKRPEKPVPPPPPIAKINGEVSSISSKFETEPVSKLKLDSEQLPLRPKSVDFDSLTVRTSKETDVVNFDDIASSENLLHLTANRPKMPGRRLPGRFNGGHSPTHSPEKILKLPKEEDSANLKPSELKKDTCYSPKPSVYLSTPSSASKANTTAFLTPLEIKAKVETDDVKKNSLDELRAQIIELLCIVEALKKDHGKELEKLRKDLEEEKTMRSNLEMEIEKLKKAVLSS DIP protein Q9Y5K6 original sequence version: 92 DIP protein Q9Y5K6 original sequence version: 94 DIP protein Q9Y5K6 original sequence version: 98 7576509C7ED5B343 cd2-cd2ap-1 3 CD2 6 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f2c f2d f2g f4e f5 cblb-cd2ap-2 3 CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Arg904Gly mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R G Tue Jul 12 10:07:48 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 15:27:10 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg904gly' Tue Jun 30 15:57:53 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg904Gly' direct interaction direct interaction mint f2c f2e f4e f7 sf1b cblb-cd2ap-3 3 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Lys907Leu mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain K L Tue Jul 12 10:06:22 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 19:44:53 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'lys907leu' Tue Jun 30 18:23:49 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Lys907Leu' CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f2c f2e f4e f7 sf1b cblb-sh3kbp1-6 3 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Arg904Gly mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R G Tue Jul 12 10:49:24 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 14:58:37 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg904gly' Tue Jun 30 16:23:53 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg904Gly' CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f2a f2b f2e f3e f7 sf1a cblb-sh3kbp1-7 3 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Arg911Ala mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R A Tue Jul 12 10:06:38 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 19:25:01 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg911ala' Tue Jun 30 16:48:27 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg911Ala' CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f2a f2b f2e f3e f7 sf1a cd2-sh3kbp1 3 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2 6 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f2b f2d f2f cd2-cd2ap-2 1 CD2 6 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f4c sf4 st2 cblb-cd2ap-4 1 CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Arg904Gly mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R G Tue Jul 12 10:54:15 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 19:29:06 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg904gly' Tue Jun 30 18:04:17 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg904Gly' direct interaction direct interaction mint f4b sf4 st2 cblb-cd2ap-5 1 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified Q13191:p.Lys907Leu mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain K L Tue Jul 12 10:54:28 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 19:21:03 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'lys907leu' Tue Jun 30 19:26:05 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Lys907Leu' binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint sf4 st2 cblb-sh3kbp1-8 1 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Arg904Gly mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R G Tue Jul 12 10:15:56 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 15:31:21 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg904gly' Tue Jun 30 16:30:27 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg904Gly' direct interaction direct interaction mint f3b sf4a st1 cblb-sh3kbp1-9 1 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Arg911Ala mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R A Tue Jul 12 10:22:36 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 16:33:34 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'arg911ala' Tue Jun 30 19:55:03 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg911Ala' CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f3d sf4a st1 cd2-sh3kbp1-1 1 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2 6 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f3a sf4a st1 cblb-cd2ap-6 1 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified Q13191:p.Arg911Ala mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain R A Tue Jul 12 10:58:17 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Tue Jun 30 17:10:43 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Arg911Ala' binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f4d sf4 st2 cblb-cd2ap-7 1 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f4c sf4 st2 cblb-sh3kbp1-10 1 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Lys907Leu mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain K L Tue Jul 12 10:58:25 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 19:44:49 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'lys907leu' Tue Jun 30 18:14:56 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Lys907Leu' direct interaction direct interaction mint sf4a st1 cblb-sh3kbp1-11 1 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint f3c sf4a st1 cblb-cd2ap-8 1 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint In the case of the interaction of CD2AP-SH3A with CD2 and Cbl-b, the SAXS data confirms the overwhelming presence of dimeric complexes as the main species in solution, with only traces of trimers. f6a f6c st3 sf2c sf2d cd2-cd2ap-3 2 CD2AP 7 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2 6 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint In the case of the interaction of CD2AP-SH3A with CD2 and Cbl-b, the SAXS data confirms the overwhelming presence of dimeric complexes as the main species in solution, with only traces of trimers. f6c st3 sf2a sf2b cd2-sh3kbp1-2 2 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CD2 6 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint CIN85-SH3A on the other hand, shows a different behavior. It interacts with CD2 to form mainly dimers in solution, however at half of the equimolar point and above, trimers account for around 10% of the population (Fig. 6 and Table S3). With Cbl-b the situation is even more peculiar. The experimental scattering curves can only be explained if we consider the presence of a trimeric complex in significantly large amounts in equilibrium with dimeric complexes. Figure 6 shows that the trimeric species dominate in solution at a 1:0.5 (SH3:peptide) molar ratio, and decreases to approximately half of the dimeric population above the equimolar point. Similar behavior was found for the interaction of CIN85-SH3A with the Cbl-bK907L peptide (Fig.6 and Fig.S2), where despite the mutation of the K907, the scattering curves still indicate the formation of a trimeric complex, in agreement with the ITC and NMR results, confirming the key role of R904 in the type I interaction. f6a f6c st3 sf2e sf2f cblb-sh3kbp1-12 2 CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain Q13191:p.Lys907Leu mutation disrupting interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain K L Tue Jul 12 10:56:58 BST 2016 This feature has been corrected as a result of our quality control procedures. The original label was 'mutation disrupting' Wed May 02 17:16:05 BST 2018 This feature has been corrected as a result of our quality control procedures. The original label was 'lys907leu' Tue Jun 30 16:21:39 BST 2020 This feature has been corrected as a result of our quality control procedures. The original label was 'p.Lys907Leu' direct interaction direct interaction mint CIN85-SH3A on the other hand, shows a different behavior. It interacts with CD2 to form mainly dimers in solution, however at half of the equimolar point and above, trimers account for around 10% of the population (Fig. 6 and Table S3). With Cbl-b the situation is even more peculiar. The experimental scattering curves can only be explained if we consider the presence of a trimeric complex in significantly large amounts in equilibrium with dimeric complexes. Figure 6 shows that the trimeric species dominate in solution at a 1:0.5 (SH3:peptide) molar ratio, and decreases to approximately half of the dimeric population above the equimolar point. Similar behavior was found for the interaction of CIN85-SH3A with the Cbl-bK907L peptide (Fig.6 and Fig.S2), where despite the mutation of the K907, the scattering curves still indicate the formation of a trimeric complex, in agreement with the ITC and NMR results, confirming the key role of R904 in the type I interaction. f6c st3 sf2i cblb-sh3kbp1-13 2 Cbl-b 4 peptide synthesis peptide synthesis experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain CIN85 5 predetermined predetermined participant predetermined experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified binding site binding region binding-associated region binding region certain certain sequence position certain certain certain sequence position certain direct interaction direct interaction mint CIN85-SH3A on the other hand, shows a different behavior. It interacts with CD2 to form mainly dimers in solution, however at half of the equimolar point and above, trimers account for around 10% of the population (Fig. 6 and Table S3). With Cbl-b the situation is even more peculiar. The experimental scattering curves can only be explained if we consider the presence of a trimeric complex in significantly large amounts in equilibrium with dimeric complexes. Figure 6 shows that the trimeric species dominate in solution at a 1:0.5 (SH3:peptide) molar ratio, and decreases to approximately half of the dimeric population above the equimolar point. Similar behavior was found for the interaction of CIN85-SH3A with the Cbl-bK907L peptide (Fig.6 and Fig.S2), where despite the mutation of the K907, the scattering curves still indicate the formation of a trimeric complex, in agreement with the ITC and NMR results, confirming the key role of R904 in the type I interaction. f6a f6c st3 sf2g sf2h